Abstract:Bromodomain (BD) is an evolutionarily conserved protein module found in 46 different BD-containing proteins (BCPs). BD acts as a specific reader for acetylated lysine residues (KAc) and serves an essential role in transcriptional regulation, chromatin remodeling, DNA damage repair, and cell proliferation. On the other hand, BCPs have been shown to be involved in the pathogenesis of a variety of diseases, including cancers, inflammation, cardiovascular diseases, and viral infections. Over the past decade, researchers have brought new therapeutic strategies to relevant diseases by inhibiting the activity or downregulating the expression of BCPs to interfere with the transcription of pathogenic genes. An increasing number of potent inhibitors and degraders of BCPs have been developed, some of which are already in clinical trials. In this paper, we provide a comprehensive review of recent advances in the study of drugs that inhibit or down-regulate BCPs, focusing on the development history, molecular structure, biological activity, interaction with BCPs and therapeutic potentials of these drugs. In addition, we discuss current challenges, issues to be addressed and future research directions for the development of BCPs inhibitors. Lessons learned from the successful or unsuccessful development experiences of these inhibitors or degraders will facilitate the further development of efficient, selective and less toxic inhibitors of BCPs and eventually achieve drug application in the clinic.

Recent Advances on Small-Molecule Bromodomain-Containing Histone Acetyltransferase Inhibitors.

Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors

Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development

Small-molecule BET Inhibitors in Clinical and Preclinical Development and Their Therapeutic Potential.

Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives

The Therapeutic Potential of BRD4 in Cardiovascular Disease

Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.

Disrupting Acetyl-lysine Interactions: Recent advance in the development of BET inhibitors.

BET Bromodomain inhibitors and degraders based on polypharmacology:research advances

Discovery and characterization of small molecule inhibitors of the BET family bromodomains

Targeting Bromodomain-Containing Proteins: Research Advances of Drug Discovery

Drug Discovery Targeting Bromodomain-Containing Protein 4

Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics

A Chemical Toolbox for the Study of Bromodomains and Epigenetic Signaling

Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8

Current development of CBP/p300 inhibitors in the last decade

CBP/p300 bromodomain: new promising epigenetic target

Selective inhibition of BET bromodomains

Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation.

Research Progress of Selective Small Molecule Bromodomain-Containing Protein 9 Inhibitors